a crucial role in follicular lymphomagenesis. In this paper, we describe a case of chronic lymphocytic leukemia showing the juxtaposition of the bcl-2 gene on chromosome 18 to immunoglobulin A light chain (IgA) gene on chromosome 22 in a head-to-head configuration. Sequencing analysis of the joining site of the bcl-2 gene and IgA gene has shown that the breakpoint is within the 5' flanking region of the bcl-2 gene and about 2.2 kilobases 5' to the joining segment of IgA locus in a germ-line configuration. The extranucleotide, commonly appearing at the joining site of the t(14;18) translocation involving the IgH locus, is absent from the joining site of bcl-2 and IgA. The lack of extranucleotide suggests that the juxtaposition of the bcl-2 and IgA genes occurred during physiological rearrangement of the IgA gene since it has been shown that the rearrangement of the IgA locus is not accompanied by extranucleotides.
Chromosomal abnormalities, predominantly translocations, deletions, and inversions, are present in most hematopoietic malignancies (1). Involvement of the immunoglobulin genes in chromosomal translocations is observed in various types of B-cell malignancies (2) (3) (4) . Burkitt lymphoma carries one of three different chromosome translocations-t(8;14) (nearly 80%), t (8;22) (15%), and t(2;8) (5%)-in all ofwhich the c-myc gene is juxtaposed to one of the three immunoglobulin loci, heavy chain (IgH), light chain A (IgA), and K chain (IgK), respectively (3) . Although the breakpoints vary among cases in the c-myc gene locus as well as immunoglobulin gene loci, a consequence of these translocations is the deregulation of c-myc gene expression. This deregulation is due to the cis effect of elements of the immunoglobulin loci (3) .
Approximately 90% of the cases of follicular lymphoma, one of the most common hematopoietic malignancies in the United States and Europe, carry the t(14;18) (q32;q21) chromosome translocation that juxtaposes the bcl-2 gene on chromosome 18 to the 5' region of the joining segment of IgH locus (4-7). The bcl-2 gene is a prime candidate for the oncogene involved in this translocation because all t(14;18) translocations studied thus far occur within or in close proximity to the bcl-2 gene (4) (5) (6) (7) (8) , and the steady-state level of the bcl-2 mRNA is elevated in cells carrying the t (14;18) translocation (8) .
Although the c-myc gene has been shown to be involved in various types of human tumors, including both hematopoietic malignancies and solid tumors, the bcl-2 gene has been implicated specifically in follicular lymphoma and diffuse large cell lymphoma. We began to elucidate the possible involvement of the bcl-2 gene in other types of hematopoietic neoplasmas, including chronic lymphocytic leukemia (CLL) and multiple myeloma. In this paper, we describe a case of a patient with CLL cells carrying a bcl-2-IgA rearrangement, representing a variant translocation involving the bcl-2 gene.
MATERIALS AND METHODS
Construction of the Genomic DNA Libraries. DNA extracted from leukemia cells of a CLL patient was partially digested with the restriction enzyme Sau3AI, and DNA fragments between 15 and 23 kilobases (kb) were collected. DNA inserts were ligated with the phage vector AEMBL3A DNA digested with BamHI, and the library was screened with the radiolabeled bcl-2 probe by nick-translation using a-32P-labeled dNTPs.
DNA Sequencing. Nucleotide sequences were determined by using the Sanger dideoxy nucleotide protocol for M13 single-stranded DNA or double-stranded DNA (9) . Sequences were analyzed by using the University of Wisconsin Genetics Computer Group software (10) .
Southern Blot Analysis. High molecular weight DNAs were cleaved with appropriate restriction enzymes, subjected to electrophoresis on 0.8% agarose gels, and transferred to nitrocellulose sheets as described (11) .
DNAs. The pB16 probe (12) is a bcl-2 cDNA clone that corresponds to the 1.6-kb 3' part of the first exon. The HuA-5 clone (13) 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tion in follicular lymphoma cluster in several regions, the major one at the 3' untranslated region of the bcl-2 gene and the minor ones 3' to the gene (4, 8, 16 ). In addition, we have also described one case of follicular lymphoma that showed the rearrangement at the 5' end of the bcl-2 first exon juxtaposed with the IgH locus (14) . During a survey ofa panel of malignant B-cell DNAs, including CLL and multiple myeloma, using different regions of bcl-2 as DNA probes, one case of CLL (CLL 1446) was found that showed the rearrangement of the first exon of the bcl-2 gene. As shown in Fig. 1, (12) . The clone A1446-3 containing the rearranged bcl-2 fragment was selected and subjected to further analysis. The structures of the germ-line clone A18-21 (14) and clone A1446-3 are illustrated in Fig. 2 . By comparison of A1446-3 DNA with A18-21 DNA, the breakpoint on chromosome 18 was located close to the 5' end of the bcl-2 gene as shown in Fig. 2 .
To elucidate the origin of the DNA sequences rearranged to the 5' end of the bcl-2 gene, we subcloned the repeatsequence free 0.7-kb BamHI fragment of the clone A1446-3 into pUC19 (pCA) (Fig. 2) . A Southern blot analysis probed with pCA demonstrated that pCA recognizes multiple fragments in human placental DNA (Fig. 3) , which are similar to the IgA constant region genes (13) . In fact, the restriction map of the region beyond the breakpoint in A1446-3 perfectly fits to the 7.6-kb EcoRI-Sac I fragment derived from a clone, HuA5, containing the normal CA locus (Fig. 2) . The nucleotide sequences were also determined from the 3' BamHI site of pCA and showed >98% homology with the sequences of CA previously published (13) Sequence Analysis of the Breakpoint. The nucleotide sequences around the joining region of the bcl-2 and IgA locus were determined and are shown in Fig. 4 . The breakpoint on chromosome 18 is located in the 5' flanking region ofthe bcl-2 gene and is close to the cap site (12, 17) . The nucleotide sequences beyond the breakpoint are identical to those of normal IgA locus. The breakpoint on chromosome 22 is at about 2.2 kb 5' to the JAl sequence. Comparison of the detailed restriction maps indicates that the IgA locus is in a germ-line configuration. Note also that no extranucleotide is found at the joining site, the bcl-2 and IgA locus; this is in contrast to the t(14;18) translocation, in which the presence of extranucleotides is more common (5-7).
DISCUSSION
It has been shown that the c-myc gene can rearrange at the 5' and 3' regions of the gene with IgH and immunoglobulin light chain (IgL) genes, respectively. In this paper, we have described a case of CLL in which the 5' end of the bcl-2 gene rearranges with the IgA locus. Thus, the bcl-2 gene can also rearrange at the 5' and 3' regions with the IgL and IgH genes, respectively. The interesting feature of these translocated bcl-2 and c-myc genes is that these genes are always located 5' to immunoglobulin constant loci. This configuration might be crucial for activation of these genes (3, 14) . We have previously shown a case of follicular lymphoma (no. 989) in which the 5' region of the bcl-2 gene rearranged with the IgH locus (14) . The orientation of the IgH locus, however, is not what is expected from the orientation of the bcl-2 and IgH genes with respect to the centromere but is opposite, and the bcl-2 gene is situated in front of the IgH locus. This observation strongly suggests the requirement of localization of the genes to be activated 5' to constant loci of immunoglobulin genes. This type of activation is not compatible with characteristics of IgH enhancer, which is orientation independent, and thus suggests the existence of a cis element different from the conventional IgH enhancer in immunoglobulin constant loci with orientation dependency for gene activation.
Sequencing analysis of thejoining point of the bcl-2 and IgA genes has shown that these two sequences were joined without any extranucleotides. This is in contrast to the situation of the rearrangement of the bcl-2 gene with the IgH locus, in which the addition of extranucleotides is more common. This might reflect the physiological situation whereby rearrangement of the IgH gene (VDJ joining, where V = variable, D = diversity, and J = joining segments) is often associated with the presence of extranucleotides (N region) (18) , whereas rearrangement of IgLs (VJ joining) is not (19) . This might suggest that the rearrangement of bcl-2 and IgA genes in CLL 1446 occurred during the physiological rearrangement of IgL gene. In this case, however, DNA sequences similar to the 7-mer-9-mer sequences recognized by V(D)J recombinase are not found around the joining site, making it unlikely that V(D)J recombinase is directly involved in the rearrangement of the bcl-2 to IgA locus in CLL 1446.
It has been shown that Burkitt lymphomas carrying the variant translocation t(2;8) and t(8;22) always produce IgK chain and A chain, respectively (20) . In one exceptional case of Burkitt-like lymphoma (PA 682), derived from a homosexual patient with acquired immunodeficiency syndrome, the t(8;22) translocation was present but produced IgK chain (21) . The The bcl-2/IgA rearrangement described in this paper is a very rare event in CLL, but it might represent a subclass of CLL. Although the bcl-2/CA rearrangement has not been described in follicular lymphoma, the cases described to show rearrangement of the bcl-2 first exon (16) might carry this type of rearrangement. The bcl-2 gene is involved in low-grade (not acute) B-cell malignancies, such as follicular lymphoma and CLL, suggesting that additional oncogenetic events are crucial in higher-grade malignancies such as acute lymphoblastic leukemia. Coactivation of c-myc and bcl-2 genes, for example, has been described in B-cell acute leukemias (22, 23) . These data imply that the bcl-2 gene might have a lower tumorigenic potential than the c-myc gene. This is consistent with our recent observation that the overproduction of the bcl-2 gene product enhances growth of an Epstein-Barr virus-transformed B-cell line but does not confer tumorigenicity (24) . Genetics: Adachi et al.
